



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Preliminary results of survey on Collaboration between Enpr-EMA networks and Industry for the conduct of Industry-funded clinical trials

Presented by: Benjamin Pelle, EMA
5th Enpr-EMA Workshop, 27 June 2013

An agency of the European Union





Aims of this survey

- To get an overview on the current **number** of Industry funded paediatric clinical trials open at the Enpr-EMA Networks
- To identify **key issues** and **barriers** affecting the collaboration between Industry and Enpr-EMA Networks to conduct Industry-funded paediatric clinical trials through the Networks
- To find **ways for a better collaboration** between Industry and the research Networks



Overview

- 2 Surveys (Survey Monkey) sent to:
 - All registered 39 Enpr-EMA Networks
 - Industry: EFPIA, EBE and EUROPABIO + (Proveca Ltd, BMS)
- Both surveys were similar (9 questions asked to the Networks and 12 questions asked to Industry)
- Both Surveys open from end of May till 14 June
- Re-open since 17 June
- Enpr-EMA Networks: **12 responses received**
- Industry: **2 responses received**


Next slides only outline PRELIMINARY responses from the
2 Networks



Information on number of Industry funded paediatric clinical trials conducted in the Networks (1 / 4)

Response Rate: 12 / 39 Networks (31 %)

- Number of trials the Networks were approached about in 2012:



Mean n = 17 [0-130]


4/12 networks were not approached

1/12 network approached 130x



Information on number of Industry funded paediatric clinical trials conducted in the Networks (2 / 4)

- Number of trials opened in Networks in 2012:



Mean n = 5 [0-44]


6/12 networks did not open trials

1/12 network opened 44 trials



Information on number of Industry funded paediatric clinical trials conducted in the Networks (3 / 4)

- Number of trials which were open in 2012:



Mean n = 10 [0-101]


7/12 networks had no open trials

1/12 network had 101 open trials



Information on number of Industry funded paediatric clinical trials conducted in the Networks (4 / 4)

- Number of participants recruited to trials in 2012:



Mean n = 150 [0-1285]

7/12 networks did not recruit any patients

1/12 network recruited 1285 patients



Views on issues which may affect the conduct of Industry funded paediatric clinical trials through Networks (1 / 2)

Answers	Strongly disagree	Disagree	Neutral	Agree	Strongly agree
My network is still under establishment	33.3% (4)	41.7% (5)	8.3% (1)	16.7% (2)	0.0% (0)
Industry fully understands the expertise the networks can offer	8.3% (1)	16.7% (2)	41.7% (5)	16.7% (2)	16.7% (2)
Industry is aware of the clinical populations that networks have access to	8.3% (1)	16.7% (2)	33.3% (4)	33.3% (4)	8.3% (1)
Industry understands what support networks can offer	8.3% (1)	16.7% (2)	50.0% (6)	25.0% (3)	0.0% (0)
Investigators fully understand what industry needs	0.0% (0)	41.7% (5)	25.0% (3)	33.3% (4)	0.0% (0)
My network prefers to conduct academic clinical trials	8.3% (1)	41.7% (5)	25.0% (3)	25.0% (3)	0.0% (0)
My network has core funding for a single coordinating centre to administer incoming requests about clinical trials or queries about patient populations	16.7% (2)	25.0% (3)	16.7% (2)	25.0% (3)	16.7% (2)
My network has core funding that ensures communication between recruitment sites	16.7% (2)	16.7% (2)	25.0% (3)	33.3% (4)	8.3% (1)
My network has core funding for staff in the recruitment sites	33.3% (4)	25.0% (3)	25.0% (3)	8.3% (1)	8.3% (1)
Networks are able to ensure communication between recruitment sites	0.0% (0)	8.3% (1)	0.0% (0)	66.7% (8)	25.0% (3)
The costs of managing incoming requests about clinical trials or queries about patient populations from industry are met by industry	16.7% (2)	50.0% (6)	25.0% (3)	8.3% (1)	0.0% (0)
Costs for the management of incoming requests about clinical trials or queries about patient populations from industry should be met by industry	0.0% (0)	0.0% (0)	41.7% (5)	50.0% (6)	8.3% (1)




Views on issues which may affect the conduct of Industry funded paediatric clinical trials through Networks (2 / 2)

Answers	Strongly disagree	Disagree	Neutral	Agree	Strongly agree
Industry currently meets the full costs of trials	8.3% (1)	41.7% (5)	25.0% (3)	16.7% (2)	8.3% (1)
Public funders or health systems should provide secure core funding for network infrastructure	0.0% (0)	8.3% (1)	16.7% (2)	58.3% (7)	16.7% (2)
Public funders or health systems should provide secure core funding for overhead costs of all trials	16.7% (2)	41.7% (5)	8.3% (1)	25.0% (3)	8.3% (1)
The administrative burdens and / or costs to obtain Ethics Committee's approval for each individual collaborating centre limit capacity to undertake trials	8.3% (1)	33.3% (4)	16.7% (2)	33.3% (4)	8.3% (1)
When seeking potential sites for trials Industry provides enough information for my network to make a decision on participation	0.0% (0)	8.3% (1)	41.7% (5)	41.7% (5)	8.3% (1)
For most enquiries my network has received from industry there are insufficient recruitment possibilities (ie on its own my network may not contain enough centres)	16.7% (2)	33.3% (4)	33.3% (4)	0.0% (0)	16.7% (2)
There is insufficient trial experience in my network for industry-funded trials	33.3% (4)	50.0% (6)	16.7% (2)	0.0% (0)	0.0% (0)
I have found that most Industry trials are not feasible	25.0% (3)	16.7% (2)	25.0% (3)	25.0% (3)	8.3% (1)
Networks lack infrastructure	16.7% (2)	33.3% (4)	33.3% (4)	16.7% (2)	0.0% (0)
Networks lack dedicated staff in the recruitment sites	16.7% (2)	8.3% (1)	33.3% (4)	33.3% (4)	8.3% (1)



Ways for a better collaboration between Industry and the Networks (1 / 4)

- Better visibility of the Networks to Industry would be achieved by outlining potential for collaboration:




Additional comments:

- Electronic newsletter
- On both websites
- MS/National Agency websites



Ways for a better collaboration between Industry and the Networks (2 / 4)

- Communication between Industry and the Networks would be best achieved:




Additional comments:

- At both meetings
- With each MS / National Agency



Ways for a better collaboration between Industry and the Networks (3 / 4)

- Previous experience of delivering Industry led paediatric clinical trials would have the greatest impact if made available:




Additional comments:

- At both websites
- At conferences



Ways for a better collaboration between Industry and the Networks (4 / 4)

- Should Enpr-EMA establish regular contact with Industry in order to highlight successes and challenges:



Additional comments:

- During workshops
- During conferences/meetings
- By newsletters with case-study
- By e-forms



Next steps

- To keep both surveys open and collect more responses from Networks and Industry, i.e. to increase response rate
- To compare responses between Networks and Industry
- To identify the main key issues and ways for a better collaboration between Networks and Industry and implement some actions